Program
omaveloxolone
Also written as “Omaveloxolone”, “Omaveloxolone Capsules, 2.5 mg” and “Omaveloxolone Capsules, 5 mg”.
Its studies are mostly in Friedreich Ataxia · Inflammation · Mitochondrial Myopathies · Melanoma · Breast Neoplasms, led by Biogen.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Biogen | 192 open or running | phase 3since Apr 11, 2025 | Dec 30, 2013 | Nov 16, 2027phase 3 · NCT06953583 |
Also a collaborator on its studies: AbbVie, celerion, q2-solutions, altasciences-company-inc and covance.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Dec 30, 2013.
- May 16, 2014Phase 2 study in Breast NeoplasmsNCT02142959 · 187 enrolled · United States
- Sep 30, 20142 phase 2 studiesNCT02255435, NCT02255422
- Oct 3, 2014Phase 2 study in MelanomaNCT02259231 · 41 enrolled · United States
- Sep 6, 2018Phase 1 study in HealthyNCT03664453 · 32 enrolled · United States
- Mar 26, 2019Phase 1 study in Hepatic ImpairmentNCT03902002 · 48 enrolled · United States
- Apr 25, 2019Phase 1 study in Healthy Male SubjectsNCT03931590 · 8 enrolled · United States
- Jul 2, 2019Phase 1 study in Healthy Adult SubjectsNCT04008186 · 61 enrolled · United States
- Jun 8, 20232 phase 1 studiesNCT05909644, NCT05927649
- Sep 13, 2023Phase 1 study in Friedreich AtaxiaNCT06054893 · 33 enrolled · United States
- Sep 23, 2024Phase 1 study in Healthy VolunteerNCT06612879 · 12 enrolled · United States
- Apr 11, 2025Phase 3 study in Friedreich AtaxiaNCT06953583 · 255 enrolled · United States, Australia, Austria and more
- Jun 5, 2025Phase 1 study in Healthy VolunteerNCT07019064 · 52 enrolled · United States
- Aug 28, 2025Phase 1 study in Healthy VolunteerNCT07149415 · 22 enrolled · United States
- Dec 9, 2025Phase 1 study in Healthy VolunteerNCT07297199 · 70 enrolled · United States
Ahead
- Nov 16, 2027Primary completion: phase 3 study in Friedreich AtaxiaNCT06953583
- Jun 4, 2030Primary completion: phase 1 study in Friedreich AtaxiaNCT06054893
TargetBeta
“Nuclear factor erythroid 2-related factor 2 activator”ChEMBL 37, by rule
Studies
All 19 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07297199Healthy Volunteer · United States | 1 | Completed | May 1, 2026 | 70 |
| NCT07149415Healthy Volunteer · United States | 1 | Completed | Oct 16, 2025 | 22 |
| NCT07019064Healthy Volunteer · United States | 1 | Completed | Aug 19, 2025 | 52 |
| NCT06953583Friedreich Ataxia · United States, Australia, Austria and more | 3 | Active, not recruiting | Nov 16, 2027 | 255 |
| NCT06612879Healthy Volunteer · United States | 1 | Completed | Mar 11, 2025 | 12 |
| NCT06054893Friedreich Ataxia · United States | 1 | Active, not recruiting | Jun 4, 2030 | 33 |
| NCT05927649Health Adult Subjects · United States | 1 | Completed | Sep 1, 2023 | 30 |
| NCT05909644Healthy Adult Subjects · United States | 1 | Completed | Aug 30, 2023 | 20 |
| NCT04008186Healthy Adult Subjects · United States | 1 | Completed | Aug 18, 2019 | 61 |
| NCT03931590Healthy Male Subjects · United States | 1 | Completed | May 31, 2019 | 8 |
| NCT03902002Hepatic Impairment · United States | 1 | Completed | Jan 27, 2020 | 48 |
| NCT03664453Healthy · United States | 1 | Completed | Nov 20, 2018 | 32 |
| NCT02259231Melanoma · United States | 2 | Completed | May 9, 2018 | 41 |
| NCT02255435Friedreich Ataxia · United States, Australia, Austria and more | 2 | Completed | Oct 31, 2019 | 172 |
| NCT02255422Mitochondrial Myopathies · United States, Denmark | 2 | Completed | Nov 2, 2017 | 53 |
| NCT02142959Breast Neoplasms · United States | 2 | Completed | Apr 30, 2015 | 187 |
| NCT02065375Inflammation · United States | 2 | Completed | Sep 30, 2014 | 109 |
| NCT02029729Neoplasm Metastasis · United States | 1 | Completed | Oct 1, 2015 | 11 |
| NCT02029716Inflammation · United States | 1 | Completed | Apr 1, 2014 | 109 |
How it is read
Names in the registry
- “Omaveloxolone”, 9 entries
- “omaveloxolone”, 2 entries
- “Omaveloxolone Capsules, 2.5 mg”, 1 entry
- “Omaveloxolone Capsules, 5 mg”, 1 entry
- “Omaveloxolone Capsules, 10 mg”, 1 entry
Conditions, from the studies’ own filings
- Friedreich Ataxia, 3 studies
- Inflammation, 2 studies
- Mitochondrial Myopathies, 1 study
- Melanoma, 1 study
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.